SCHEMBL10070937

SCHEMBL10070937

CCCCOc1c(C(=O)OC)nc2c(N3CCN(C(=O)OC(C)(C)C)CC3=O)cc(NCC3CC3)cn2c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.40
PDE7A Q13946 1/20 0.40
MERTK Q12866 2/20 0.32
CNR2 P34972 1/20 0.32
ENPP2 Q13822 2/20 0.32
SYK P43405 1/20 0.32
GPR119 Q8TDV5 5/20 0.32
PIK3CD O00329 1/20 0.31
BCDIN3D Q7Z5W3 1/20 0.31
SUV39H2 Q9H5I1 1/20 0.31
TBK1 Q9UHD2 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
ALDH1A1 P00352 1/20 0.31
HPGD P15428 1/20 0.31
KMT2A Q03164 1/20 0.31
NR1H2 P55055 1/20 0.31
MAPT P10636 1/20 0.31
FLT3 P36888 1/20 0.31
TYRO3 Q06418 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL369125 0.89 PRMT5 (0.41) PDE4BPDE7AGPR119KDM4E
SCHEMBL15101376 0.86 PDE4B (0.39) PDE4BPDE7AENPP2GPR119PIK3CD
SCHEMBL10069920 0.86 PDE4B (0.40) PDE4BPDE7AENPP2NR1H2MAPT
SCHEMBL10069876 0.85 PDE4B (0.40) PDE4BPDE7AENPP2GPR119SUV39H2
SCHEMBL10069924 0.85 PDE4B (0.39) PDE4BPDE7AENPP2SUV39H2NR1H2
SCHEMBL10069923 0.84 PDE4B (0.41) PDE4BPDE7AENPP2SUV39H2MEN1
SCHEMBL10071000 0.84 PDE4B (0.41) PDE4BPDE7AENPP2SUV39H2MEN1
SCHEMBL15101649 0.83 PDE4B (0.39) PDE4BPDE7AENPP2SUV39H2ALDH1A1
SCHEMBL10070065 0.82 PDE4B (0.39) PDE4BPDE7AENPP2PIK3CD
SCHEMBL10069925 0.81 PIK3R1 (0.38) PDE4BPDE7AENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY (SIOC) (CN) 2013-07-11 US disclosed
WO-2012006680-A1 7, 9-NITROGEN RADICAL-4-OXO-4H-PYRIDO[L,2-A]PYRIMIDINE-2-CARBOXYLIC ACID BENZYLAMIDE ANTI-VIRALS AVEXA LIMITED (AU) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178469-A1 NOVEL ANTIVIRAL AGENTS EIF2AK2, IFNAR1, IRF3 PDE4B 209/4885PDE7A 200/4885MERTK 3678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.